Results 201 to 210 of about 102,703 (336)

Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer

Yuexin Wang, Maya Gross, Renata R. Urban, Soledad Jorge   +3 more
openalex   +1 more source

Implementation of an enhanced recovery after surgery (ERAS) program in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: study protocol for a prospective multicenter interventional trial (EPICH study) [PDF]

Manuela Robella, Eva Pagano, Lisa Giacometti, Armando Cinquegrana, Luca Pellegrino, Andrea Evangelista, Alessandra Saliva, Alessandro Kim Cerutti, Felice Borghi   +8 more
openalex   +1 more source

Colorectal Cancer Cell's Weapon: RNF32 Engages SPP1+ Macrophages to Foster Liver Metastasis, Targeted by Indole‐3‐Acetic Acid

Advanced Science, EarlyView.
Cytoplasmic RNF32 fuels CRC liver metastasis by degrading GSK3β, which stabilizes β‐catenin and activates Wnt/EMT. Moreover, RNF32 rewires the metastatic niche: it depletes CD8+/CD4+ T and NK cells while recruiting SPP1+ macrophages (which boost tumor stemness via CD44), fibroblasts, and immunosuppressive monocytes to aid colonization.
Hongyu Wang, Shipeng Dai, Yuchen Xie, Pengyu Chen, Yue Chai, Chongyu Wang, Xueying Huang, Xiao Dong, Junfeng Shi, Yongxiang Xia, Xiaofeng Qian, Weiwei Tang, Yichan Zhou   +12 more
wiley   +1 more source

The Role of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal GIST-Induced Sarcomatosis (GISTosis). [PDF]

J Clin Med
Spiliotis J, Kopanakis N, Rogdakis A, Peppas G, Fotiadou A, Evangelou K, Vassos N.   +6 more
europepmc   +1 more source

Traceless Regulation of Genetic Circuitry

Advanced Science, EarlyView.
Energy‐based, as opposed to molecular, control offers unprecedented improvements in key circuit parameters. This review summarizes the fundamentals of such traceless switches, categorizes them by trigger modalities, and compares and contrasts distinct advantages as well as shortcomings of each kind.
Gokberk Unal, Martin Fussenegger
wiley   +1 more source

A Clinical Pharmacological Perspective on Intraperitoneal Chemotherapy. [PDF]

Drugs
Rietveld PCS, Guchelaar NAD, Sassen SDT, Koch BCP, Mathijssen RHJ, Koolen SLW.   +5 more
europepmc   +1 more source

Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review [PDF]

, 2020
Eliza W. Beal, Lorena P. Suarez‐Kelly, Charles W. Kimbrough, Fabian M. Johnston, Jonathan B. Greer, Daniel E. Abbott, Courtney Pokrzywa, Mustafa Raoof, Byrne Lee, Travis E. Grotz, Jennifer L. Leiting, Keith F. Fournier, Andrew Lee, Seán Dineen, Benjamin D. Powers, Jula Veerapong, Joel Baumgartner, Callisia N. Clarke, Harveshp Mogal, Marti C. Russell, M. Zaidi, Sameer H. Patel, Vikrom K. Dhar, Laura Lambert, Ryan J. Hendrix, John L. Hays, Sherif Abdel‐Misih, Jordan M. Cloyd   +27 more
openalex   +1 more source

ADAMTS9‐AS2 Disrupts Docetaxel‐Resistance in Castration‐Resistant Prostate Cancer via Stemness Suppression and Ferroptosis Induction

Advanced Science, EarlyView.
This study uncovered a dual‐track mechanism by which ADAMTS9‐AS2 overcame chemoresistance in CRPC: suppressing cancer stemness through the FOXF2/TGF‐β2 pathway, and triggering ferroptosis via competitive SLC7A11 sequestration. Polymeric materials co‐targeting these vulnerabilities further boost docetaxel sensitivity, highlighting a compelling strategy ...
Ji Liu, Yan Gao, Yadong Guo, Junfeng Zhang, Wentao Zhang, Zhuoran Gu, Haotian Chen, Chengqi Jin, Peng Luo, Shiyu Mao, Yajuan Hao, Shuo Shi, Xudong Yao   +12 more
wiley   +1 more source

Quality of life following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a Canadian experience. [PDF]

Can J Surg
Taqi K, Stockley C, Fyfe A, Temple W, Mack L, Bouchard-Fortier A.   +5 more
europepmc   +1 more source

Targeted Degradation of eEF2K by a Structure‐Guided PROTAC Strategy for the Treatment of Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study developed an eEF2K‐targeting PROTAC, A6, that efficiently degrades eEF2K in TNBC cells, inhibiting tumor growth in vitro and in vivo. To enhance tumor‐specific delivery, we engineered A6@ZIF‐8, a pH‐sensitive nanocarrier, which improved drug accumulation at tumor sites, offering a promising therapeutic strategy for TNBC through targeted ...
Shijun Cao, Changxin Zhong, Shilong Jiang, Yungui Li, Yang Xi, Mingxuan Xiao, Ting Jiang, Xiaoya Wan, Zonglin Chen, Xiaohui Yu, Yan Cheng   +10 more
wiley   +1 more source